UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Exposing drug industry funding of UK patient organisations

BMJ (Online), 2019-05, Vol.365, p.l1806

2019

Link zum Volltext

Verfügbarkeit prüfen

Short-circuiting biology: Digital phenotypes, digital biomarkers, and shifting gazes in psychiatry

Big data & society, 2023-01, Vol.10 (1), p.205395172211456

Mulinari, Shai

2023

Link zum Volltext

Verfügbarkeit prüfen

The will of Congress? Permissive regulation and the strategic use of labeling for the anti-influenza drug Relenza

Social studies of science, 2020-02, Vol.50 (1), p.145-169

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database

PloS one, 2023-11, Vol.18 (11), p.e0290022-e0290022

2023

Link zum Volltext

Verfügbarkeit prüfen

Conceptual unclarity about COVID-19 ethnic disparities in Sweden: Implications for public health policy

Health (London, England : 1997), 2023-03, Vol.27 (2), p.186-200

2023

Link zum Volltext

Verfügbarkeit prüfen

Drug company payments to General Practices in England: Cross-sectional and social network analysis

PloS one, 2021-12, Vol.16 (12), p.e0261077-e0261077

2021

Link zum Volltext

Verfügbarkeit prüfen

Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs

PloS one, 2020-06, Vol.15 (6), p.e0235021-e0235021

2020

Link zum Volltext

Verfügbarkeit prüfen

Capitalizing on transparency: Commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act

Big data & society, 2022-01, Vol.9 (1), p.205395172110696

2022

Link zum Volltext

Verfügbarkeit prüfen

Pharmaceutical lobbying and pandemic stockpiling: A feeling of déjà vu in the Nordic countries and why the sociological perspective is crucial to understand COVID-19

Acta sociologica, 2020-11, Vol.63 (4), p.439-442

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012

PLoS medicine, 2016-01, Vol.13 (1), p.e1001945-e1001945

2016

Link zum Volltext

Verfügbarkeit prüfen

International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency

Globalization and health, 2023-03, Vol.19 (1), p.14-14, Article 14

2023

Link zum Volltext

Verfügbarkeit prüfen

Complaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004-2012: a quantitative and qualitative study of pharmaceutical industry self-regulation

PLoS medicine, 2015-02, Vol.12 (2), p.e1001785-e1001785

2015

Link zum Volltext

Verfügbarkeit prüfen

Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016)

BMJ open, 2020-09, Vol.10 (9), p.e037351-e037351

2020

Link zum Volltext

Verfügbarkeit prüfen

Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of 'deep' product reviews

Health research policy and systems, 2017-11, Vol.15 (1), p.93-93, Article 93

2017

Link zum Volltext

Verfügbarkeit prüfen

Regulatory scientists' work has important ramifications for public health and should be open to public scrutiny

Health research policy and systems, 2018-11, Vol.16 (1), p.98-98, Article 98

2018

Link zum Volltext

Verfügbarkeit prüfen

Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries

International journal of health policy and management, 2018-06, Vol.7 (6), p.504-509

2018

Link zum Volltext

Verfügbarkeit prüfen

Correction: Content and strength of conflict of interest policies at scandinavian medical schools: a cross sectional study

BMC medical education, 2023-03, Vol.23 (1), p.140-140, Article 140

2023

Link zum Volltext

Verfügbarkeit prüfen

Content and strength of conflict of interest policies at Scandinavian medical schools: a cross sectional study

BMC medical education, 2022-11, Vol.22 (1), p.812-7, Article 812

2022

Link zum Volltext

Verfügbarkeit prüfen

Chronic Obstructive Pulmonary Disease in Sweden: An intersectional multilevel analysis of individual heterogeneity and discriminatory accuracy

SSM - population health, 2018-04, Vol.4, p.334-346

2018

Link zum Volltext

Verfügbarkeit prüfen

Misleading advertising for antidepressants in Sweden: a failure of pharmaceutical industry self-regulation

PloS one, 2013-05, Vol.8 (5), p.e62609-e62609

2013

Link zum Volltext

Verfügbarkeit prüfen

Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe

International journal of health policy and management, 2022-12, Vol.11 (12), p.2842-2859

2022

Link zum Volltext

Verfügbarkeit prüfen

The tyranny of the averages and the indiscriminate use of risk factors in public health: The case of coronary heart disease

SSM - population health, 2017-12, Vol.3 (C), p.684-698

2017

Link zum Volltext

Verfügbarkeit prüfen

The making of a Swedish strategy: How organizational culture shaped the Public Health Agency's pandemic response

SSM. Qualitative research in health, 2022-12, Vol.2, p.100082-100082, Article 100082

2022

Link zum Volltext

Verfügbarkeit prüfen

Does Maternal Country of Birth Matter for Understanding Offspring's Birthweight? A Multilevel Analysis of Individual Heterogeneity in Sweden

PloS one, 2015-05, Vol.10 (5), p.e0129362-e0129362

2015

Link zum Volltext

Verfügbarkeit prüfen

Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry’s Disclosure UK database, 2015 and 2016 cohorts

BMJ open, 2018-10, Vol.8 (10), p.e023094-e023094

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(75)

Publikationsform

Artikel
(78)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Exposing drug industry funding of UK patient organisations

Short-circuiting biology: Digital phenotypes, digital biomarkers, and shifting gazes in psychiatry

The will of Congress? Permissive regulation and the strategic use of labeling for the anti-influenza drug Relenza

Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database

Conceptual unclarity about COVID-19 ethnic disparities in Sweden: Implications for public health policy

Drug company payments to General Practices in England: Cross-sectional and social network analysis

Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs

Capitalizing on transparency: Commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act

Pharmaceutical lobbying and pandemic stockpiling: A feeling of déjà vu in the Nordic countries and why the sociological perspective is crucial to understand COVID-19

Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012

International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency

Complaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004-2012: a quantitative and qualitative study of pharmaceutical industry self-regulation

Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016)

Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of 'deep' product reviews

Regulatory scientists' work has important ramifications for public health and should be open to public scrutiny

Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries

Correction: Content and strength of conflict of interest policies at scandinavian medical schools: a cross sectional study

Content and strength of conflict of interest policies at Scandinavian medical schools: a cross sectional study

Chronic Obstructive Pulmonary Disease in Sweden: An intersectional multilevel analysis of individual heterogeneity and discriminatory accuracy

Misleading advertising for antidepressants in Sweden: a failure of pharmaceutical industry self-regulation

Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe

The tyranny of the averages and the indiscriminate use of risk factors in public health: The case of coronary heart disease

The making of a Swedish strategy: How organizational culture shaped the Public Health Agency's pandemic response

Does Maternal Country of Birth Matter for Understanding Offspring's Birthweight? A Multilevel Analysis of Individual Heterogeneity in Sweden

Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry’s Disclosure UK database, 2015 and 2016 cohorts

Suchergebnisse filtern